Mujtaba, M. A.Sharfuddin, A. A.Taber, T.Chen, J.Phillips, C. L.Goble, M.Fridell, J. A.2020-10-132020-10-132014-11Mujtaba, M. A., Sharfuddin, A. A., Taber, T., Chen, J., Phillips, C. L., Goble, M., & Fridell, J. A. (2014). Conversion From Tacrolimus to Belatacept to Prevent the Progression of Chronic Kidney Disease in Pancreas Transplantation: Case Report of Two Patients. American Journal of Transplantation, 14(11), 2657–2661. https://doi.org/10.1111/ajt.12863https://hdl.handle.net/1805/24070Belatacept is a novel immunosuppressive agent that may be used as an alternative to calcineurin inhibitors (CNI) in immunosuppression (IS) regimens. We report two cases of pancreas transplant that were switched from tacrolimus (TAC) to belatacept. Case 1: 38‐year‐old female with pancreas transplant alone maintained on TAC‐based IS regimen whose serum creatinine (SCr) slowly deteriorated from 0.6 mg/dL at baseline to 2.2 mg/dL, 16 months posttransplant. A native kidney biopsy performed showed CNI toxicity. The patient was started on belatacept and TAC was eliminated. Case 2: 49‐year‐old female with simultaneous pancreas–kidney transplant, maintained on TAC‐based regimen where the SCr worsened over an initial 3‐month period from a baseline of 1.0 to 3.0 mg/dL. Belatacept was started and TAC was lowered. Due to persistent graft dysfunction and kidney transplant biopsy still showing changes consistent with CNI toxicity, the TAC was then discontinued. At >1 year postbelatacept and off TAC follow‐up, kidney function as measured by SCr remains stable at 1.0 ± 0.2 mg/dL in both recipients. Neither patient developed rejection following the switch, and pancreas allograft function remains stable in both recipients.enPublisher Policyclinical research/practiceimmunosuppression/immune modulationkidney transplantation/nephrologyArticle